The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).
 
A. Dasari
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen
Research Funding - Ipsen (Inst); Novartis (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Merrimack; sirtex Medical
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche
 
David R. Fogelman
No Relationships to Disclose
 
Bryan K. Kee
No Relationships to Disclose
 
David Menter
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
No Relationships to Disclose
 
Van Karlyle Morris
No Relationships to Disclose
 
Jisu Oh
No Relationships to Disclose
 
Ji Wu
No Relationships to Disclose
 
Zhiqin Jiang
No Relationships to Disclose
 
Feng Tian
No Relationships to Disclose
 
Liana Adam
No Relationships to Disclose
 
Mary Brimer
No Relationships to Disclose
 
Jeffrey Morris
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Scott Kopetz
Consulting or Advisory Role - Agendia; Amgen; Array BioPharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merrimack; Roche; Sanofi; Sysmex; Taiho Pharmaceutical
Research Funding - Agendia; Amgen; Biocartis; GlaxoSmithKline; Guardant Health; Roche; Sanofi; Sysmex